AAPL323.12+6.27 (+1.98%) ▲|ABBV259.94+3.52 (+1.37%) ▲|ABT109.72-0.65 (-0.58%) ▼|ACN188.13-1.63 (-0.86%) ▼|ADBE288.66-4.13 (-1.41%) ▼|AMAT444.40-13.99 (-3.05%) ▼|AMD457.06-13.66 (-2.90%) ▼|AMGN433.06+3.18 (+0.74%) ▲|AMT175.51-0.19 (-0.11%) ▼|AMZN254.66-5.12 (-1.97%) ▼|AVGO367.78-2.56 (-0.69%) ▼|AXP326.86-3.32 (-1.00%) ▼|BA206.77-1.01 (-0.49%) ▼|BAC62.37+0.43 (+0.69%) ▲|BKNG199.46+0.37 (+0.18%) ▲|BLK1,136.45-19.16 (-1.66%) ▼|BMY67.03+0.22 (+0.32%) ▲|BNY160.60-0.68 (-0.42%) ▼|BRK-B504.70+0.67 (+0.13%) ▲|C133.09+1.47 (+1.11%) ▲|CAT781.69-15.78 (-1.98%) ▼|CL90.56+0.74 (+0.83%) ▲|CMCSA26.55-0.07 (-0.26%) ▼|COF213.56-0.96 (-0.45%) ▼|COP135.00+2.51 (+1.89%) ▲|COST945.38+1.49 (+0.16%) ▲|CRM257.80+0.26 (+0.10%) ▲|CSCO109.17-1.33 (-1.20%) ▼|CVS97.09+3.18 (+3.39%) ▲|CVX208.95+2.81 (+1.36%) ▲|DE672.81+17.90 (+2.73%) ▲|DHR209.33-4.24 (-1.98%) ▼|DIS107.52-0.03 (-0.03%) ▼|DUK120.65+0.74 (+0.61%) ▲|EMR149.65-2.79 (-1.83%) ▼|FDX324.60-2.80 (-0.86%) ▼|GD369.27-2.09 (-0.56%) ▼|GE331.05-4.66 (-1.39%) ▼|GEV884.54-13.99 (-1.56%) ▼|GILD148.38+2.04 (+1.39%) ▲|GM86.22-0.10 (-0.12%) ▼|GOOG332.96-2.45 (-0.73%) ▼|GOOGL336.07-3.29 (-0.97%) ▼|GS1,021.55+0.65 (+0.06%) ▲|HD321.78-6.06 (-1.85%) ▼|HON210.33-3.20 (-1.50%) ▼|IBM231.12-2.75 (-1.18%) ▼|INTC88.80-0.71 (-0.79%) ▼|INTU349.87-9.43 (-2.62%) ▼|ISRG368.92-7.94 (-2.11%) ▼|JNJ268.15+2.30 (+0.86%) ▲|JPM358.40+2.38 (+0.67%) ▲|KO88.53-0.14 (-0.16%) ▼|LIN483.89-5.69 (-1.16%) ▼|LLY1,171.93+15.20 (+1.31%) ▲|LMT551.37-6.41 (-1.15%) ▼|LOW201.78-2.92 (-1.43%) ▼|LRCX291.64-9.85 (-3.27%) ▼|MA587.12-2.19 (-0.37%) ▼|MCD261.14-0.54 (-0.21%) ▼|MDLZ62.38+0.31 (+0.50%) ▲|MDT91.80+1.15 (+1.27%) ▲|META578.60+6.26 (+1.09%) ▲|MMM170.74-1.09 (-0.63%) ▼|MO70.38+1.90 (+2.77%) ▲|MRK149.39+1.63 (+1.10%) ▲|MS214.04+0.72 (+0.34%) ▲|MSFT501.12-6.18 (-1.22%) ▼|MU954.46-4.28 (-0.45%) ▼|NEE82.79+0.45 (+0.55%) ▲|NFLX80.88-0.18 (-0.22%) ▼|NKE38.36-0.30 (-0.76%) ▼|NOW143.09-4.91 (-3.31%) ▼|NVDA218.48-2.02 (-0.92%) ▼|ORCL142.52-6.60 (-4.43%) ▼|PEP140.01-0.33 (-0.24%) ▼|PFE28.64+0.18 (+0.61%) ▲|PG147.83+2.71 (+1.87%) ▲|PLTR183.27-3.11 (-1.67%) ▼|PM190.77+3.47 (+1.85%) ▲|QCOM165.61-4.87 (-2.86%) ▼|RTX206.16-1.58 (-0.76%) ▼|SBUX105.83-0.42 (-0.40%) ▼|SCHW108.78-1.04 (-0.95%) ▼|SO88.11+0.11 (+0.13%) ▲|SPG213.04+0.72 (+0.34%) ▲|T26.07+0.18 (+0.70%) ▲|TMO604.86-12.24 (-1.98%) ▼|TMUS181.95+1.51 (+0.84%) ▲|TSLA359.27-8.68 (-2.36%) ▼|TXN253.38-7.53 (-2.89%) ▼|UBER75.44-0.21 (-0.28%) ▼|UNH395.95+6.54 (+1.68%) ▲|UNP293.91-6.76 (-2.25%) ▼|UPS102.78-1.46 (-1.40%) ▼|USB61.23-0.36 (-0.58%) ▼|V376.86-2.52 (-0.66%) ▼|VZ50.30+0.28 (+0.55%) ▲|WFC86.87+0.48 (+0.55%) ▲|WMT106.07+1.20 (+1.14%) ▲|XOM163.12+2.17 (+1.35%) ▲|AAPL323.12+6.27 (+1.98%) ▲|ABBV259.94+3.52 (+1.37%) ▲|ABT109.72-0.65 (-0.58%) ▼|ACN188.13-1.63 (-0.86%) ▼|ADBE288.66-4.13 (-1.41%) ▼|AMAT444.40-13.99 (-3.05%) ▼|AMD457.06-13.66 (-2.90%) ▼|AMGN433.06+3.18 (+0.74%) ▲|AMT175.51-0.19 (-0.11%) ▼|AMZN254.66-5.12 (-1.97%) ▼|AVGO367.78-2.56 (-0.69%) ▼|AXP326.86-3.32 (-1.00%) ▼|BA206.77-1.01 (-0.49%) ▼|BAC62.37+0.43 (+0.69%) ▲|BKNG199.46+0.37 (+0.18%) ▲|BLK1,136.45-19.16 (-1.66%) ▼|BMY67.03+0.22 (+0.32%) ▲|BNY160.60-0.68 (-0.42%) ▼|BRK-B504.70+0.67 (+0.13%) ▲|C133.09+1.47 (+1.11%) ▲|CAT781.69-15.78 (-1.98%) ▼|CL90.56+0.74 (+0.83%) ▲|CMCSA26.55-0.07 (-0.26%) ▼|COF213.56-0.96 (-0.45%) ▼|COP135.00+2.51 (+1.89%) ▲|COST945.38+1.49 (+0.16%) ▲|CRM257.80+0.26 (+0.10%) ▲|CSCO109.17-1.33 (-1.20%) ▼|CVS97.09+3.18 (+3.39%) ▲|CVX208.95+2.81 (+1.36%) ▲|DE672.81+17.90 (+2.73%) ▲|DHR209.33-4.24 (-1.98%) ▼|DIS107.52-0.03 (-0.03%) ▼|DUK120.65+0.74 (+0.61%) ▲|EMR149.65-2.79 (-1.83%) ▼|FDX324.60-2.80 (-0.86%) ▼|GD369.27-2.09 (-0.56%) ▼|GE331.05-4.66 (-1.39%) ▼|GEV884.54-13.99 (-1.56%) ▼|GILD148.38+2.04 (+1.39%) ▲|GM86.22-0.10 (-0.12%) ▼|GOOG332.96-2.45 (-0.73%) ▼|GOOGL336.07-3.29 (-0.97%) ▼|GS1,021.55+0.65 (+0.06%) ▲|HD321.78-6.06 (-1.85%) ▼|HON210.33-3.20 (-1.50%) ▼|IBM231.12-2.75 (-1.18%) ▼|INTC88.80-0.71 (-0.79%) ▼|INTU349.87-9.43 (-2.62%) ▼|ISRG368.92-7.94 (-2.11%) ▼|JNJ268.15+2.30 (+0.86%) ▲|JPM358.40+2.38 (+0.67%) ▲|KO88.53-0.14 (-0.16%) ▼|LIN483.89-5.69 (-1.16%) ▼|LLY1,171.93+15.20 (+1.31%) ▲|LMT551.37-6.41 (-1.15%) ▼|LOW201.78-2.92 (-1.43%) ▼|LRCX291.64-9.85 (-3.27%) ▼|MA587.12-2.19 (-0.37%) ▼|MCD261.14-0.54 (-0.21%) ▼|MDLZ62.38+0.31 (+0.50%) ▲|MDT91.80+1.15 (+1.27%) ▲|META578.60+6.26 (+1.09%) ▲|MMM170.74-1.09 (-0.63%) ▼|MO70.38+1.90 (+2.77%) ▲|MRK149.39+1.63 (+1.10%) ▲|MS214.04+0.72 (+0.34%) ▲|MSFT501.12-6.18 (-1.22%) ▼|MU954.46-4.28 (-0.45%) ▼|NEE82.79+0.45 (+0.55%) ▲|NFLX80.88-0.18 (-0.22%) ▼|NKE38.36-0.30 (-0.76%) ▼|NOW143.09-4.91 (-3.31%) ▼|NVDA218.48-2.02 (-0.92%) ▼|ORCL142.52-6.60 (-4.43%) ▼|PEP140.01-0.33 (-0.24%) ▼|PFE28.64+0.18 (+0.61%) ▲|PG147.83+2.71 (+1.87%) ▲|PLTR183.27-3.11 (-1.67%) ▼|PM190.77+3.47 (+1.85%) ▲|QCOM165.61-4.87 (-2.86%) ▼|RTX206.16-1.58 (-0.76%) ▼|SBUX105.83-0.42 (-0.40%) ▼|SCHW108.78-1.04 (-0.95%) ▼|SO88.11+0.11 (+0.13%) ▲|SPG213.04+0.72 (+0.34%) ▲|T26.07+0.18 (+0.70%) ▲|TMO604.86-12.24 (-1.98%) ▼|TMUS181.95+1.51 (+0.84%) ▲|TSLA359.27-8.68 (-2.36%) ▼|TXN253.38-7.53 (-2.89%) ▼|UBER75.44-0.21 (-0.28%) ▼|UNH395.95+6.54 (+1.68%) ▲|UNP293.91-6.76 (-2.25%) ▼|UPS102.78-1.46 (-1.40%) ▼|USB61.23-0.36 (-0.58%) ▼|V376.86-2.52 (-0.66%) ▼|VZ50.30+0.28 (+0.55%) ▲|WFC86.87+0.48 (+0.55%) ▲|WMT106.07+1.20 (+1.14%) ▲|XOM163.12+2.17 (+1.35%) ▲|
24.1 C
New York
Tuesday, September 1, 2026

Tag: disorders

newssourceFORcompanyinformationcontent1releasesmarket

Cognision Publishes Landmark Study Showing Ketamine Produces Opposite Brain Effects in Different Patients — and That Outcome Can Be Predicted Using EEG

LOUISVILLE, Ky., June 11, 2026 /PRNewswire/ -- Cognision, a leader in neurophysiological biomarker research, today announced the publication of a landmark study in Biological...

Novo Nordisk: Wegovy® pill (semaglutide tablets) becomes first daily GLP-1 weight-loss pill approved in the UK

Novo Nordisk's Wegovy® pill has been approved in the UK as an adjunct to a reduced-calorie diet and increased physical activity for adults

Cosmos Health Secures Additional 180-Day Nasdaq Extension to Regain Bid Price Compliance

Cosmos Health secures additional 180-day Nasdaq extension to regain compliance.

Scenic Biotech Joins Michael J. Fox Foundation’s LITE Program to Explore New Disease-Modifying Approach for Parkinson’s Disease

Scenic Biotech Joins Michael J. Fox Foundation’s LITE Program to Explore New Disease-Modifying Approach for Parkinson's Disease

Formosa Pharmaceuticals Announces Licensing Agreement with Samil Pharmaceuticals, Co., Ltd, for Commercialization of Clobetasol Propionate Ophthalmic Suspension for the Treatment of Inflammation and Pain...

TAIPEI, June 11, 2026 /PRNewswire/ -- Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TW) announced today that the company has entered into an exclusive licensing agreement with Samil...

IMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven...

Patients in the IMAAVY 30 mg/kg treatment groupa achieved statistically significant durable hemoglobin responseb, with mean hemoglobin improvement of at least 1 g/dL as...

Vivoryon Therapeutics N.V. Reports Q1 2026 Financial Results and Provides Business Update

Vivoryon Therapeutics N.V. Reports Q1 2026 Financial Results
and Provides Business Update

Teva Closes Acquisition of Emalex Biosciences, Strengthening Late-Stage Neuroscience Pipeline and Advancing Pivot to Growth Strategy 

TEL AVIV, Israel, June 10, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the closing of Teva’s acquisition of Emalex Biosciences, strengthening its late-stage pipeline with ecopipam and further advancing its Pivot to Growth strategy. Phase 3 data for ecopipam were recently published in JAMA Neurology, and a U.S. NDA submission is anticipated in the second half of 2026. 

FDA approves Lilly’s EBGLYSS® (lebrikizumab-lbkz) for one maintenance dose every eight weeks in patients with moderate-to-severe atopic dermatitis

EBGLYSS is now the only approved option that offers as few as six maintenance injections per year with no required topicals from the startINDIANAPOLIS,...

Allergy/Immunology Leaders Unite to Strengthen the Specialty Workforce and Expand Access to High Quality Care

Allergy/Immunology organizations share their commitment to support the specialty workforce, quality care, and continued improvement in clinical outcomesWASHINGTON, June 9, 2026 /PRNewswire/ -- Leaders...

Selagine Plasma to Advance Pooled Plasma Eye Drops for Moderate-to-Severe Dry Eye

Agreement with Selagine, Inc. supports the development of an investigational pooled plasma biologic platform intended to move beyond individualized compounded serum tearsCHICAGO, June 9,...

Vivos Therapeutics To Participate in the Small Cap Showcase & WTR Insights on June 9, 2026

Vivos Therapeutics To Participate in the Small Cap Showcase & WTR Insights on June 9, 2026

Homeless Vets Welcome Here: AI City Hall Project Moves on Omni-AI Microcities (Veterans First for America)

Homeless Vets Welcome Here: AI City Hall Project Moves on Omni-AI Microcities (Veterans First for America)

Foresee’s Oral ALDH2 Activator, Mirivadelgat to Enter Clinical Testing in Parkinson’s Disease in the SLEIPNIR Phase 2a Platform Trial

TAIPEI, June 8, 2026 /PRNewswire/ -- Foresee Pharmaceuticals (6576.TWO), ("Foresee") announced today that Foresee's oral ALDH2 activator, mirivadelgat, has been selected to enter clinical testing in...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsDisorders

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers